Copyright Reports & Markets. All rights reserved.

Global Epirubicin Hydrochloride Injection Market Research Report 2022

Request for Sample of this report
Buy now

Table of Contents

    1 Epirubicin Hydrochloride Injection Market Overview

    • 1.1 Product Overview and Scope of Epirubicin Hydrochloride Injection
    • 1.2 Epirubicin Hydrochloride Injection Segment by Type
      • 1.2.1 Global Epirubicin Hydrochloride Injection Sales Growth Rate Comparison by Type (2022-2028)
      • 1.2.2 5mg
      • 1.2.3 10mg
    • 1.3 Epirubicin Hydrochloride Injection Segment by Application
      • 1.3.1 Global Epirubicin Hydrochloride Injection Sales Comparison by Application: (2022-2028)
      • 1.3.2 Leukemia
      • 1.3.3 Malignant Lymphoma
      • 1.3.4 Multiple Myeloma
      • 1.3.5 Breast Cancer
      • 1.3.6 Lung Cancer
      • 1.3.7 Soft Tissue Sarcoma
      • 1.3.8 Stomach Cancer
      • 1.3.9 Colorectal Cancer
      • 1.3.10 Ovarian Cancer
      • 1.3.11 Others
    • 1.4 Global Epirubicin Hydrochloride Injection Market Size Estimates and Forecasts
      • 1.4.1 Global Epirubicin Hydrochloride Injection Revenue 2017-2028
      • 1.4.2 Global Epirubicin Hydrochloride Injection Sales 2017-2028
      • 1.4.3 Epirubicin Hydrochloride Injection Market Size by Region: 2017 Versus 2021 Versus 2028

    2 Epirubicin Hydrochloride Injection Market Competition by Manufacturers

    • 2.1 Global Epirubicin Hydrochloride Injection Sales Market Share by Manufacturers (2017-2022)
    • 2.2 Global Epirubicin Hydrochloride Injection Revenue Market Share by Manufacturers (2017-2022)
    • 2.3 Global Epirubicin Hydrochloride Injection Average Price by Manufacturers (2017-2022)
    • 2.4 Manufacturers Epirubicin Hydrochloride Injection Manufacturing Sites, Area Served, Product Type
    • 2.5 Epirubicin Hydrochloride Injection Market Competitive Situation and Trends
      • 2.5.1 Epirubicin Hydrochloride Injection Market Concentration Rate
      • 2.5.2 The Global Top 5 and Top 10 Largest Epirubicin Hydrochloride Injection Players Market Share by Revenue
      • 2.5.3 Global Epirubicin Hydrochloride Injection Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    • 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

    3 Epirubicin Hydrochloride Injection Retrospective Market Scenario by Region

    • 3.1 Global Epirubicin Hydrochloride Injection Retrospective Market Scenario in Sales by Region: 2017-2022
    • 3.2 Global Epirubicin Hydrochloride Injection Retrospective Market Scenario in Revenue by Region: 2017-2022
    • 3.3 North America Epirubicin Hydrochloride Injection Market Facts & Figures by Country
      • 3.3.1 North America Epirubicin Hydrochloride Injection Sales by Country
      • 3.3.2 North America Epirubicin Hydrochloride Injection Revenue by Country
      • 3.3.3 United States
      • 3.3.4 Canada
    • 3.4 Europe Epirubicin Hydrochloride Injection Market Facts & Figures by Country
      • 3.4.1 Europe Epirubicin Hydrochloride Injection Sales by Country
      • 3.4.2 Europe Epirubicin Hydrochloride Injection Revenue by Country
      • 3.4.3 Germany
      • 3.4.4 France
      • 3.4.5 U.K.
      • 3.4.6 Italy
      • 3.4.7 Russia
    • 3.5 Asia Pacific Epirubicin Hydrochloride Injection Market Facts & Figures by Region
      • 3.5.1 Asia Pacific Epirubicin Hydrochloride Injection Sales by Region
      • 3.5.2 Asia Pacific Epirubicin Hydrochloride Injection Revenue by Region
      • 3.5.3 China
      • 3.5.4 Japan
      • 3.5.5 South Korea
      • 3.5.6 India
      • 3.5.7 Australia
      • 3.5.8 China Taiwan
      • 3.5.9 Indonesia
      • 3.5.10 Thailand
      • 3.5.11 Malaysia
    • 3.6 Latin America Epirubicin Hydrochloride Injection Market Facts & Figures by Country
      • 3.6.1 Latin America Epirubicin Hydrochloride Injection Sales by Country
      • 3.6.2 Latin America Epirubicin Hydrochloride Injection Revenue by Country
      • 3.6.3 Mexico
      • 3.6.4 Brazil
      • 3.6.5 Argentina
    • 3.7 Middle East and Africa Epirubicin Hydrochloride Injection Market Facts & Figures by Country
      • 3.7.1 Middle East and Africa Epirubicin Hydrochloride Injection Sales by Country
      • 3.7.2 Middle East and Africa Epirubicin Hydrochloride Injection Revenue by Country
      • 3.7.3 Turkey
      • 3.7.4 Saudi Arabia
      • 3.7.5 UAE

    4 Global Epirubicin Hydrochloride Injection Historic Market Analysis by Type

    • 4.1 Global Epirubicin Hydrochloride Injection Sales Market Share by Type (2017-2022)
    • 4.2 Global Epirubicin Hydrochloride Injection Revenue Market Share by Type (2017-2022)
    • 4.3 Global Epirubicin Hydrochloride Injection Price by Type (2017-2022)

    5 Global Epirubicin Hydrochloride Injection Historic Market Analysis by Application

    • 5.1 Global Epirubicin Hydrochloride Injection Sales Market Share by Application (2017-2022)
    • 5.2 Global Epirubicin Hydrochloride Injection Revenue Market Share by Application (2017-2022)
    • 5.3 Global Epirubicin Hydrochloride Injection Price by Application (2017-2022)

    6 Key Companies Profiled

    • 6.1 Akorn
      • 6.1.1 Akorn Corporation Information
      • 6.1.2 Akorn Description and Business Overview
      • 6.1.3 Akorn Epirubicin Hydrochloride Injection Sales, Revenue and Gross Margin (2017-2022)
      • 6.1.4 Akorn Epirubicin Hydrochloride Injection Product Portfolio
      • 6.1.5 Akorn Recent Developments/Updates
    • 6.2 Aurobindo Pharma
      • 6.2.1 Aurobindo Pharma Corporation Information
      • 6.2.2 Aurobindo Pharma Description and Business Overview
      • 6.2.3 Aurobindo Pharma Epirubicin Hydrochloride Injection Sales, Revenue and Gross Margin (2017-2022)
      • 6.2.4 Aurobindo Pharma Epirubicin Hydrochloride Injection Product Portfolio
      • 6.2.5 Aurobindo Pharma Recent Developments/Updates
    • 6.3 Cipla
      • 6.3.1 Cipla Corporation Information
      • 6.3.2 Cipla Description and Business Overview
      • 6.3.3 Cipla Epirubicin Hydrochloride Injection Sales, Revenue and Gross Margin (2017-2022)
      • 6.3.4 Cipla Epirubicin Hydrochloride Injection Product Portfolio
      • 6.3.5 Cipla Recent Developments/Updates
    • 6.4 Ebewe Pharma
      • 6.4.1 Ebewe Pharma Corporation Information
      • 6.4.2 Ebewe Pharma Description and Business Overview
      • 6.4.3 Ebewe Pharma Epirubicin Hydrochloride Injection Sales, Revenue and Gross Margin (2017-2022)
      • 6.4.4 Ebewe Pharma Epirubicin Hydrochloride Injection Product Portfolio
      • 6.4.5 Ebewe Pharma Recent Developments/Updates
    • 6.5 Fresenius Kabi Usa
      • 6.5.1 Fresenius Kabi Usa Corporation Information
      • 6.5.2 Fresenius Kabi Usa Description and Business Overview
      • 6.5.3 Fresenius Kabi Usa Epirubicin Hydrochloride Injection Sales, Revenue and Gross Margin (2017-2022)
      • 6.5.4 Fresenius Kabi Usa Epirubicin Hydrochloride Injection Product Portfolio
      • 6.5.5 Fresenius Kabi Usa Recent Developments/Updates
    • 6.6 Impax Laboratories
      • 6.6.1 Impax Laboratories Corporation Information
      • 6.6.2 Impax Laboratories Description and Business Overview
      • 6.6.3 Impax Laboratories Epirubicin Hydrochloride Injection Sales, Revenue and Gross Margin (2017-2022)
      • 6.6.4 Impax Laboratories Epirubicin Hydrochloride Injection Product Portfolio
      • 6.6.5 Impax Laboratories Recent Developments/Updates
    • 6.7 Mylan Laboratories
      • 6.6.1 Mylan Laboratories Corporation Information
      • 6.6.2 Mylan Laboratories Description and Business Overview
      • 6.6.3 Mylan Laboratories Epirubicin Hydrochloride Injection Sales, Revenue and Gross Margin (2017-2022)
      • 6.4.4 Mylan Laboratories Epirubicin Hydrochloride Injection Product Portfolio
      • 6.7.5 Mylan Laboratories Recent Developments/Updates
    • 6.8 Nippon Kayaku
      • 6.8.1 Nippon Kayaku Corporation Information
      • 6.8.2 Nippon Kayaku Description and Business Overview
      • 6.8.3 Nippon Kayaku Epirubicin Hydrochloride Injection Sales, Revenue and Gross Margin (2017-2022)
      • 6.8.4 Nippon Kayaku Epirubicin Hydrochloride Injection Product Portfolio
      • 6.8.5 Nippon Kayaku Recent Developments/Updates
    • 6.9 Pfizer
      • 6.9.1 Pfizer Corporation Information
      • 6.9.2 Pfizer Description and Business Overview
      • 6.9.3 Pfizer Epirubicin Hydrochloride Injection Sales, Revenue and Gross Margin (2017-2022)
      • 6.9.4 Pfizer Epirubicin Hydrochloride Injection Product Portfolio
      • 6.9.5 Pfizer Recent Developments/Updates
    • 6.10 Sawai Pharmaceutical
      • 6.10.1 Sawai Pharmaceutical Corporation Information
      • 6.10.2 Sawai Pharmaceutical Description and Business Overview
      • 6.10.3 Sawai Pharmaceutical Epirubicin Hydrochloride Injection Sales, Revenue and Gross Margin (2017-2022)
      • 6.10.4 Sawai Pharmaceutical Epirubicin Hydrochloride Injection Product Portfolio
      • 6.10.5 Sawai Pharmaceutical Recent Developments/Updates
    • 6.11 Zennova
      • 6.11.1 Zennova Corporation Information
      • 6.11.2 Zennova Epirubicin Hydrochloride Injection Description and Business Overview
      • 6.11.3 Zennova Epirubicin Hydrochloride Injection Sales, Revenue and Gross Margin (2017-2022)
      • 6.11.4 Zennova Epirubicin Hydrochloride Injection Product Portfolio
      • 6.11.5 Zennova Recent Developments/Updates
    • 6.12 Beijing Union Pharmaceutical Factory
      • 6.12.1 Beijing Union Pharmaceutical Factory Corporation Information
      • 6.12.2 Beijing Union Pharmaceutical Factory Epirubicin Hydrochloride Injection Description and Business Overview
      • 6.12.3 Beijing Union Pharmaceutical Factory Epirubicin Hydrochloride Injection Sales, Revenue and Gross Margin (2017-2022)
      • 6.12.4 Beijing Union Pharmaceutical Factory Epirubicin Hydrochloride Injection Product Portfolio
      • 6.12.5 Beijing Union Pharmaceutical Factory Recent Developments/Updates
    • 6.13 Hisun Pharmaceutical
      • 6.13.1 Hisun Pharmaceutical Corporation Information
      • 6.13.2 Hisun Pharmaceutical Epirubicin Hydrochloride Injection Description and Business Overview
      • 6.13.3 Hisun Pharmaceutical Epirubicin Hydrochloride Injection Sales, Revenue and Gross Margin (2017-2022)
      • 6.13.4 Hisun Pharmaceutical Epirubicin Hydrochloride Injection Product Portfolio
      • 6.13.5 Hisun Pharmaceutical Recent Developments/Updates
    • 6.14 Hanhui Pharmaceutical
      • 6.14.1 Hanhui Pharmaceutical Corporation Information
      • 6.14.2 Hanhui Pharmaceutical Epirubicin Hydrochloride Injection Description and Business Overview
      • 6.14.3 Hanhui Pharmaceutical Epirubicin Hydrochloride Injection Sales, Revenue and Gross Margin (2017-2022)
      • 6.14.4 Hanhui Pharmaceutical Epirubicin Hydrochloride Injection Product Portfolio
      • 6.14.5 Hanhui Pharmaceutical Recent Developments/Updates
    • 6.15 Lunan Pharmaceutical
      • 6.15.1 Lunan Pharmaceutical Corporation Information
      • 6.15.2 Lunan Pharmaceutical Epirubicin Hydrochloride Injection Description and Business Overview
      • 6.15.3 Lunan Pharmaceutical Epirubicin Hydrochloride Injection Sales, Revenue and Gross Margin (2017-2022)
      • 6.15.4 Lunan Pharmaceutical Epirubicin Hydrochloride Injection Product Portfolio
      • 6.15.5 Lunan Pharmaceutical Recent Developments/Updates

    7 Epirubicin Hydrochloride Injection Manufacturing Cost Analysis

    • 7.1 Epirubicin Hydrochloride Injection Key Raw Materials Analysis
      • 7.1.1 Key Raw Materials
      • 7.1.2 Key Suppliers of Raw Materials
    • 7.2 Proportion of Manufacturing Cost Structure
    • 7.3 Manufacturing Process Analysis of Epirubicin Hydrochloride Injection
    • 7.4 Epirubicin Hydrochloride Injection Industrial Chain Analysis

    8 Marketing Channel, Distributors and Customers

    • 8.1 Marketing Channel
    • 8.2 Epirubicin Hydrochloride Injection Distributors List
    • 8.3 Epirubicin Hydrochloride Injection Customers

    9 Epirubicin Hydrochloride Injection Market Dynamics

    • 9.1 Epirubicin Hydrochloride Injection Industry Trends
    • 9.2 Epirubicin Hydrochloride Injection Market Drivers
    • 9.3 Epirubicin Hydrochloride Injection Market Challenges
    • 9.4 Epirubicin Hydrochloride Injection Market Restraints

    10 Global Market Forecast

    • 10.1 Epirubicin Hydrochloride Injection Market Estimates and Projections by Type
      • 10.1.1 Global Forecasted Sales of Epirubicin Hydrochloride Injection by Type (2023-2028)
      • 10.1.2 Global Forecasted Revenue of Epirubicin Hydrochloride Injection by Type (2023-2028)
    • 10.2 Epirubicin Hydrochloride Injection Market Estimates and Projections by Application
      • 10.2.1 Global Forecasted Sales of Epirubicin Hydrochloride Injection by Application (2023-2028)
      • 10.2.2 Global Forecasted Revenue of Epirubicin Hydrochloride Injection by Application (2023-2028)
    • 10.3 Epirubicin Hydrochloride Injection Market Estimates and Projections by Region
      • 10.3.1 Global Forecasted Sales of Epirubicin Hydrochloride Injection by Region (2023-2028)
      • 10.3.2 Global Forecasted Revenue of Epirubicin Hydrochloride Injection by Region (2023-2028)

    11 Research Finding and Conclusion

      12 Methodology and Data Source

      • 12.1 Methodology/Research Approach
        • 12.1.1 Research Programs/Design
        • 12.1.2 Market Size Estimation
        • 12.1.3 Market Breakdown and Data Triangulation
      • 12.2 Data Source
        • 12.2.1 Secondary Sources
        • 12.2.2 Primary Sources
      • 12.3 Author List

      Summary:

      Industry Insights
      Due to the COVID-19 pandemic, the global Epirubicin Hydrochloride Injection market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Epirubicin Hydrochloride Injection market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Epirubicin Hydrochloride Injection landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
      5mg accounting for % of the Epirubicin Hydrochloride Injection global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Leukemia segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
      The global major manufacturers of Epirubicin Hydrochloride Injection include Akorn, Aurobindo Pharma, Cipla, Ebewe Pharma, Fresenius Kabi Usa, Impax Laboratories, Mylan Laboratories, Nippon Kayaku and Pfizer, etc. In terms of revenue, the global 3 largest players have a % market share of Epirubicin Hydrochloride Injection in 2021.
      This report focuses on Epirubicin Hydrochloride Injection volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Epirubicin Hydrochloride Injection market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
      Key Drivers & Barriers
      High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
      Post-covid-19 Outlook
      The readers in the section will understand how the Epirubicin Hydrochloride Injection market scenario changed across the globe during the pandemic and post-pandemic. The study is done keeping in view the changes in aspects such as sales, demand and supply chain. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
      Segmental Outlook
      Key segments including type and application have been elaborated in this report. The consultants at QY Research have studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and application during the historical period (2017-2022) and forecast period (2023-2028).
      Segment by Type
      5mg
      10mg
      Segment by Application
      Leukemia
      Malignant Lymphoma
      Multiple Myeloma
      Breast Cancer
      Lung Cancer
      Soft Tissue Sarcoma
      Stomach Cancer
      Colorectal Cancer
      Ovarian Cancer
      Others
      Regional Outlook
      This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2017-2028. This information derived through comprehensive research will help the reader to get familiar with the potential value of the investment in a particular region.
      North America
      United States
      Canada
      Europe
      Germany
      France
      U.K.
      Italy
      Russia
      Asia-Pacific
      China
      Japan
      South Korea
      India
      Australia
      China Taiwan
      Indonesia
      Thailand
      Malaysia
      Latin America
      Mexico
      Brazil
      Argentina
      Middle East & Africa
      Turkey
      Saudi Arabia
      UAE
      Competitive Scenario
      In this section, the readers will gain an understanding of the key players competing. The experts at QY Research have studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
      Akorn
      Aurobindo Pharma
      Cipla
      Ebewe Pharma
      Fresenius Kabi Usa
      Impax Laboratories
      Mylan Laboratories
      Nippon Kayaku
      Pfizer
      Sawai Pharmaceutical
      Zennova
      Beijing Union Pharmaceutical Factory
      Hisun Pharmaceutical
      Hanhui Pharmaceutical
      Lunan Pharmaceutical
      Frequently Asked Questions
      Which product segment grabbed the largest share in the Epirubicin Hydrochloride Injection market?
      How is the competitive scenario of the Epirubicin Hydrochloride Injection market?
      Which are the key factors aiding the Epirubicin Hydrochloride Injection market growth?
      Which are the prominent players in the Epirubicin Hydrochloride Injection market?
      Which region holds the maximum share in the Epirubicin Hydrochloride Injection market?
      What will be the CAGR of the Epirubicin Hydrochloride Injection market during the forecast period?
      Which application segment emerged as the leading segment in the Epirubicin Hydrochloride Injection market?
      What key trends are likely to emerge in the Epirubicin Hydrochloride Injection market in the coming years?
      What will be the Epirubicin Hydrochloride Injection market size by 2028?
      Which company held the largest share in the Epirubicin Hydrochloride Injection market?
      Buy now